Last updated on September 2017

Phase II Study of BNC210 in PTSD

Brief description of study

This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.

Clinical Study Identifier: NCT02933606

Contact Investigators or Research Sites near you

Start Over

Michael Meade, BSc

Toowong, Australia
  Connect »